Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06054217 · ClinicalTrials.gov registry record · Phase 2

Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

A Phase 2 study of Meibomian Gland Dysfunction and Blepharitis, sponsored by Tarsus Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
36
Enrollment target
2
Study locations

NCT06054217 is a Phase 2 study of Meibomian Gland Dysfunction and Blepharitis that is active but no longer recruiting, run by Tarsus Pharmaceuticals. The registered enrollment target is 36 participants, below the 98-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (63% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06054217, a Phase 2 study of Meibomian Gland Dysfunction and Blepharitis, is active but no longer recruiting, sponsored by Tarsus Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
36 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to evaluate and compare the effect of two dosing regimens, BID versus TID dosing, of an Exploratory Vehicle (EV) on meibomian gland dysfunction (MGD) in patients with Demodex lid infestation.

Conditions Studied

Meibomian Gland Dysfunction Blepharitis Demodex Infestation of Eyelid Demodectic Blepharitis

Interventions

  • DRUG Vehicle of TP-03

Study Locations (2)

California

  • Shultz Chang Vision - Northridge

North Carolina

  • Vita Eye Clinic - Shelby

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2023-08-01
Est. Completion 2024-06-15
Phase Phase 2

Sponsor

Tarsus Pharmaceuticals

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06054217

The ClinicalTrials.gov registry entry for NCT06054217 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (63% lower). The listed sponsor is Tarsus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which Vehicle of TP-03 is the first listed.

NCT06054217 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06054217 about?

NCT06054217 is a clinical study titled "Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex". The purpose of this study is to evaluate and compare the effect of two dosing regimens, BID versus TID dosing, of an Exploratory Vehicle (EV) on meibomian gland dysfunction (MGD) in patients with Demodex lid infestation.

What is the current status of trial NCT06054217?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2023-08-01. Estimated completion is 2024-06-15.

What conditions does trial NCT06054217 study?

This clinical trial studies the following conditions: Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation of Eyelid, Demodectic Blepharitis.

What interventions are being tested in trial NCT06054217?

The interventions under investigation include: Vehicle of TP-03 (DRUG).

Who is sponsoring clinical trial NCT06054217?

This trial is sponsored by Tarsus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06054217 being conducted?

This trial has 2 study locations across California, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Meibomian Gland Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Meibomian Gland Dysfunction

All registered trials for this condition

Blepharitis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.